Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

2001 • 1,801 citations

Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety

2001 • 1,538 citations

Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism

2003 • 885 citations

Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery<subtitle>A Meta-analysis of 4 Randomized Double-blind Studies</subtitle>

2002 • 735 citations

Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery

2001 • 629 citations

Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture Surgery

2001 • 617 citations

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial

2002 • 535 citations

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

2002 • 388 citations

A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement

2001 • 381 citations

The Unique Antithrombin III Binding Domain of Heparin: A Lead to New Synthetic Antithrombotics

1993 • 376 citations

Duration of Prophylaxis Against Venous Thromboembolism With Fondaparinux After Hip Fracture Surgery<subtitle>A Multicenter, Randomized, Placebo-Controlled, Double-blind Study</subtitle>

2003 • 342 citations

Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers

2002 • 327 citations

Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence.

2001 • 267 citations

The Pharmacokinetics of Fondaparinux Sodium in Healthy Volunteers

2002 • 197 citations

A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study

2001 • 172 citations

Biological Properties of the Naturally Occurring Plasma Inhibitor to Activated Factor X

1971 • 164 citations

Pharmacokinetics and Tolerance of the Natural Pentasaccharide (SR90107/ORG31540) with High Affinity to Antithrombin III in Man

1995 • 154 citations

Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia

1997 • 118 citations

Absence of Placental Transfer of Pentasaccharide (Fondaparinux, Arixtra®) in the Dually Perfused Human Cotyledon in vitro

2002 • 103 citations

DX-9065a, an Orally Active, Specific Inhibitor of Factor Xa, Inhibits Thrombosis without Affecting Bleeding Time in Rats

1995 • 103 citations

BIOCHEMICAL AND PHARMACOLOGIC RATIONALE FOR THE DEVELOPMENT OF A SYNTHETIC HEPARIN PENTASACCHARIDE

1997 • 98 citations

SR 90107A/Org 31540, a Novel Anti‐Factor Xa Antithrombotic Agent

1997 • 93 citations

Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity - A phase II evaluation

2000 • 87 citations

Effects of Fondaparinux Compared with Dalteparin, Enoxaparin and Unfractionated Heparin on Human Osteoblasts

2003 • 85 citations

Biochemical and Pharmacological Characterization of YM-60828, a Newly Synthesized and Orally Active Inhibitor of Human Factor Xa

1998 • 81 citations

The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery

2003 • 78 citations

Synthetic Pentasaccharides Do Not Cause Platelet Activation by Antiheparin-Platelet Factor 4 Antibodies

1999 • 78 citations

The Effect of the Synthetic Pentasaccharide SR 90107/ORG 31540 on Thrombin Generation Ex Vivo Is Uniquely due to ATIII-Mediated Neutralization of Factor Xa

1995 • 77 citations

Efficacy of a Synthetic Pentasaccharide, a Pure Factor Xa Inhibitor, as an Antithrombotic Agent – A Pilot Study in the Setting of Coronary Angioplasty

1999 • 76 citations

Fondaparinux Sodium Mechanism of Action

2002 • 74 citations

The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity

1988 • 67 citations

Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase.

1997 • 66 citations

Aortic Thrombosis as a Complication of Paroxysmal Nocturnal Hemoglobinuria

2001 • 63 citations

The Action of a Synthetic Pentasaccharide on Thrombin Generation in Whole Plasma

1989 • 60 citations

Antithrombotic Effects of Synthetic Pentasaccharide with High Affinity for Plasma Antithrombin III in Non-Human Primates

1993 • 44 citations

Fondaparinux Sodium Is Not Metabolised in Mammalian Liver Fractions and Does Not Inhibit Cytochrome P450-Mediated Metabolism of Concomitant Drugs

2002 • 38 citations

<i>Neuroepidemiology</i> Advances into the 21st Century

2001 • 37 citations

Absence of Interaction of Fondaparinux Sodium with Digoxin in Healthy Volunteers

2002 • 32 citations

Absence of Interaction of Fondaparinux Sodium with Aspirin and Piroxicam in Healthy Male Volunteers

2002 • 31 citations

Synthetic Analogues of the Antithrombin III– Binding Pentasaccharide Sequence of Heparin

1995 • 30 citations

Comparative Inhibition of Extrinsic and Intrinsic Thrombin Generation by Standard Heparin, a Low Molecular Weight Heparin and the Synthetic ATIII-Binding Pentasaccharide

1993 • 27 citations

The Synthetic Pentasaccharide Fondaparinux Sodium Does Not Interact with Oral Warfarin*

2002 • 19 citations